Ebru Atasever Akkas

Ebru Atasever Akkas

Auto-generated profile, based on publicly available information

Ebru Atasever Akkas

Department of Radiation Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 April 2021 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
EAEbru Atasever Akkas
Ebru Atasever Akkas
BYBirsen Yucel
Birsen Yucel

16 June 2020 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PHPervin Hurmuz
Pervin Hurmuz
MCMustafa Cengiz
Mustafa Cengiz
GOGokhan Ozyigit
Gokhan Ozyigit
EAEbru Atasever Akkas
Ebru Atasever Akkas
DYDeniz Yuce
Deniz Yuce
FAFadil Akyol
Fadil Akyol
Purpose: Stereotactic body radiotherapy (SBRT) is an effective treatment option for patients with early-stage non-small cell lung cancer (NSCLC). In this study, we evaluated the treatment results using two different SBRT techniques and the effect of beam-on time (BOT) on treatment outcomes. Methods: Between July 2007 and January 2018, 142 patients underwent SBRT for primary NSCLC. We have delivered SBRT using either respiratory tracking system (RTS) or internal-target-volume (ITV)-based motion management techniques. The effect of age, tumor size, pretreatment tumor SUVmax value, presence of tissue diagnosis, histopathological subtype, operability status, tumor location, motion management technique, BED10 value, BOT on overall survival (OS), loco-regional control (LRC), event-free survival (EFS) and primary tumor control (PTC) were evaluated. Results: Median age of the patients was 70 years (range, 39–91 years). Most of the patients were inoperable (90%) at the time of SBRT. Median BED10 value was 112.5 Gy. With a median follow-up of 25 months, PTC was achieved in 91.5% of the patients. Two-year estimated OS, LRC, PTC and EFS rates were 68, 63, 63 and 53%, respectively. For the entire group, OS was associated with BOT (P = 0.027), and EFS was associated with BOT (P = 0.027) and tumor size (P = 0.015). For RTS group, OS was associated with age (P = 0.016), EFS with BOT (P = 0.05) and tumor size (P = 0.024), LRC with BOT (P = 0.008) and PTC with BOT (P = 0.028). The treatment was well tolerated in general. Conclusion: SBRT is an effective and safe treatment with high OS, LRC, EFS and PTC rates in patients with primary NSCLC. Protracted BOT might deteriorate SBRT outcomes.

6 July 2024 in Journal of Bone Oncology
Verified
Journal Article
Open access
SCSelma Cakmakci
Selma Cakmakci
NSNeriman Sarı
Neriman Sarı
EAEbru Atasever Akkaş
Ebru Atasever Akkaş
FYFATİH YILDIZ
FATİH YILDIZ
EKEbru Karakaya
Ebru Karakaya
IIİnci Ergürhan İlhan
İnci Ergürhan İlhan
Objectives: The present study evaluates the clinical outcomes of children, adolescents and adults with Ewing sarcoma and identifies the prognostic factors. Methods: Included in the study were 222 pediatric and adult patients diagnosed with Ewing sarcoma (EwS) who were followed up between 1992 and 2019, and whose data were analyzed retrospectively. Results: The median age of 131 male and 91 female patients included in the study was 13 (1–64). The median follow-up duration of the survivors was 79 months (range, 11–182 months). The 3-year EFS rate of the 222 patients was 34 % (Confidence Interval (CI) (0.158–0.242 %) and the OS rate was 54 % (CI, 0.289–0.590 %). For the non-metastatic patients, the 3-year EFS rate was 47 % and the OS was 68 %, while for the metastatic patients the 3-year EFS rate was 13 % and the OS was 30 %. Of the patient sample, 81 (36, 5 %) survived, of whom 72 were continuously free of disease while the disease persisted in nine, and three developed a second neoplasm (2 of whom subsequently died while one survived disease-free). Of the 129 patients who relapsed with metastases and/or local recurrence, eight survived and are disease-free, nine are alive with uncontrolled disease; five were lost to follow-up and 107 died. Conclusion: The findings of the present study suggest metastatic disease at presentation and positive margins after surgery to be of prognostic significance in ES. Disruptions in aggressive local treatments may reduce the chances of cure in EwS.